Health Plan Notification and Feedback to Providers is Associated with Increased Filling of Preventer Medications for Children with Asthma Enrolled in Medicaid
Objective
To test the hypothesis that children enrolled in Medicaid managed care health plans that provide asthma-specific communication to providers would be more likely to have adequate asthma medication filling.
Study Design
We conducted a historical cohort study of 4498 children (2-17 years old) with moderate-severe asthma in Washington State and Tennessee Medicaid managed care programs from 2000 to 2002. Interviews with health plans were conducted to identify communication strategies health plans used to improve asthma care by providers in the plan. The main outcome measure was guideline-recommended filling of asthma preventer medications.
Results
Children in plans that provided specific feedback to providers about asthma quality and notified providers when children had an asthma-related event had the highest mean days plus or minus SE of filling in the 365-day follow-up period (164.6 ± 13 days) compared with children in plans with neither (135.3 ± 10.8 days; P < .05). In children with the greatest asthma severity, enrollment in a plan with both features was associated with 27.1 additional days of filling (95% CI, 0.7-53.4 days) during the follow-up period.
Conclusion
Health plan communication to providers was associated with increased preventer filling in children with moderate-severe asthma in 2 state Medicaid programs.
Abbreviations: HCFA, Health Care Financing Administration, ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification, MMC, Medicaid managed care
To access this article, please choose from the options below
Conflicts of Interest: Drs Ray and Arbogast report receiving grant support from Pfizer for work unrelated to the research reported in this manuscript.
Supported by the Agency for Healthcare Research and Quality (HS#13076) and the Agency for Healthcare Research and Quality, Centers for Education and Research on Therapeutics (HS#10384). The funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review, or approval of the manuscript. The first draft was written by Dr Cooper.
PII: S0022-3476(07)00847-5
doi:10.1016/j.jpeds.2007.08.046
© 2008 Mosby, Inc. All rights reserved.
